Is Instinct Bio Technical Co. Holdings Inc. (BIOT) a Buy, Sell, or Hold?
NASDAQ : BIOT
Instinct Bio Technical Co. Holdings Inc. — News
$0.4019 USD
$0.0 (0.1%)
- Volume
- 407.27K
- Average Volume
- 1.59M
- Market Capitalization
- $1.73M
- P/E Ratio
- -0.96
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $50.00
- Year Low
- $0.38
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $0.95
| Source | Headline |
|---|---|
|
Instinct Bio Announces Strategic Collaboration with PT PARVA CANDELA to Develop Cosmetics Business in Indonesia
NEW YORK and TOKYO, Aug. 10, 2026 (GLOBE NEWSWIRE) -- INSTINCT BIO TECHNICAL COMPANY HOLDINGS INC. (Nasdaq: BIOT) ("Instinct Bio" or the "Company") today announced a cooperation agreement with PT PARVA CANDELA ("PARVA"), an Indonesian cosmetics manufacturer and distributor, to jointly develop Indonesia's cosmetics and personal care market under a "Made in Indonesia, Powered by Japanese Formulation Expertise" concept. globenewswire.com - 2026-08-10 07:00:00 |
|
BIOT to Launch Indonesia’s First Subscription-Model Beauty Clinics Under Its Own Japanese Brand “GENRÊVER CLINIC” — Building a Recurring-Revenue Platform in One of Asia’s Fastest-Growing Aesthetics Markets
NEW YORK and TOKYO, July 29, 2026 (GLOBE NEWSWIRE) -- INSTINCT BIO TECHNICAL COMPANY HOLDINGS INC. (NASDAQ: BIOT) ("Instinct Bio" or the "Company") today announced its decision to bring its own Japanese aesthetic healthcare brand "GENRÊVER CLINIC" to Indonesia and, together with a local Indonesian physician, to launch a subscription-model membership beauty clinic business. globenewswire.com - 2026-07-29 10:28:19 |
|
BIOT to Launch Indonesia's First Subscription-Model Beauty Clinics Under Its Own Japanese Brand “GENRÊVER CLINIC” — Building a Recurring-Revenue Platform in One of Asia's Fastest-Growing Aesthetics Markets
BIOT to Launch Indonesia's First Subscription-Model Beauty Clinics Under Its Own Japanese Brand “GENRÊVER CLINIC” Building a Recurring-Revenue Platform globenewswire.com - 2026-07-29 10:28:00 |
|
Instinct Bio (Nasdaq: BIOT) Secures $150 Million Equity Funding to Advance Regenerative Medicine Platform and Strategic Growth
Transformative funding agreement equips Instinct Bio with discretionary capital to scale its longevity-focused ecosystem and capture market opportunities. Transformative funding agreement equips Instinct Bio with discretionary capital to scale its longevity-focused ecosystem and capture market opportunities. globenewswire.com - 2026-07-28 10:01:00 |
